[Research progress of non-invasive examination in the screening of chronic liver disease among the general community population]

Zhonghua Gan Zang Bing Za Zhi. 2021 Sep 20;29(9):825-829. doi: 10.3760/cma.j.cn501113-20210826-00430.
[Article in Chinese]

Abstract

Due to its insidious nature, chronic liver disease usually only appears after a decompensating event, and delays in diagnosis lead to a high mortality. Non-invasive examination can help diagnose and intervene early stage liver fibrosis in patients with chronic liver disease. In a hospital population, this test has been widely used and appropriate; however, its value is unclear in the general community population. In recent years, there have been many studies on non-invasive examinations for foreign community populations. These non-invasive examination tools can screen patients with chronic liver disease and liver cirrhosis among the general community population. Further studies have found that screening community populations with liver disease risk factors (heavy alcohol consumption, type 2 diabetes mellitus, and obesity) can more efficiently screen out patients with chronic liver disease in the community population. In brief, these noninvasive examination can find a large number of previously undiscovered liver disease patients in the community population, compared to traditional community screening that rely on abnormal liver function testing. This paper discusses the non-invasive examination in the screening of chronic liver disease among the community population, so as to find a pioneering community non-invasive liver disease screening path for our country.

慢性肝病由于其发病的隐匿性,经常在出现失代偿事件后才就诊从而导致其死亡率居高不下。肝纤维化无创检查可以帮助慢性肝病患者早期诊断及干预。这些检查在医院人群中得到了广泛验证,但它们在社区人群中的价值尚不清楚。近年来,国外已有许多针对社区人群进行无创检查的研究,这些无创检查工具均能在社区人群中筛查出慢性肝病及肝硬化患者。进一步研究发现,针对具有肝病危险因素(大量饮酒、2型糖尿病、肥胖)的社区人群进行筛查,能更加高效地筛出社区人群中的慢性肝病患者。总之,相较于传统的依赖于异常肝功能化验的社区筛查,无创检查可以在社区人群中发现到大量之前未被发现的肝病患者。针对无创检查在社区人群中筛查慢性肝病展开讨论,以便于在我国寻找一条开创性的社区无创肝病筛查路径。.

Keywords: Chronic liver disease; Community population; Noninvasive test; Screening pathway.

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Humans
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / epidemiology
  • Liver Diseases* / diagnosis
  • Liver Diseases* / epidemiology
  • Mass Screening